Page 20 - Peptide News Today : Breaking News, Live Updates & Top Stories | Vimarsana

For the day about half an hour ago. Thats good, right to cnns Brynn Gingras in new yorks is outside the court. Brynn, what are you hearing . Why are they still in session there . Still trying to find that jury, jake, you know, at the beginning of the day, it was unclear if there was going to be a single juror seated. And now by today, at this moment, there are six that are seeded, included putting a fourperson so the process is continuing at this very hour. Some of the details about the six people that we know about so far. Of course, they remain anonymous, but one is originally from ireland, ...

finalize the war. there is a diplomatic way, and there is the military way. so any healthy and sane person always chooses diplomatic way because he or she knows even if it's hard, it may stop the losses of thousands, of tens of thousands. and with such neighbors, hundreds of thousands and maybe millions of victims. victims, losses of people, we don't want that. and any leader, whether he wants that or not, he doesn't have the right to deny it subjectively because it will be a subjective decision to deny the diplomatic way. and it's also important for our partners, i may say, because ...

Novartis AG is bolstering its radioligand arsenal with the takeout of Mariana Oncology Inc. for $1 billion up front and as much as $750 million in potential milestone payments. Watertown, Mass.-based Mariana has developed peptide-based radiopharmaceuticals targeting solid tumors. The company’s lead program, MC-339, is a radioligand approach to small-cell lung cancer, due to enter the clinic later this year.

Novartis Pharma AG continues to build up its radiopharmaceutical powerhouse and has expanded a peptide discovery collaboration with Peptidream Inc. in a deal worth up to $2.71 billion. Under the multi-program agreement, Kawasaki, Japan-based Peptidream will use its peptide discovery platform system technology to identify and optimize novel macrocyclic peptides against targets selected by Novartis for potential conjugation to radioligand therapies or other applications for both therapeutic and diagnostic purposes.

A recent breakthrough at the University of California, Riverside (UCR) could represent a turning point in the fight against cancer. Researchers have discovered a promising method...